[1]
Elizabeth Weesner et al. 2022. Injection Site Reaction to Extended-Release Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration.
Kansas Journal of Medicine. 15, 2 (Aug. 2022), 302–304. DOI:
https://doi.org/10.17161/kjm.vol15.17931.